BMS-986446 This clinical trial’s goal is to determine the impact BMS-986446 on cognitive and functional decline in participants with early Alzheimer’s disease. BMS-986446 is an anti-MTBR Tau Monoclonal antibody. Eligibility: Individuals who have mild cognitive impairment (MCI) or early Alzheimer’s…
ACU193 This clinical trial examines ACU193 for how it affects individuals with mild Alzheimer’s disease or mild cognitive impairment (MCI). This new antibody binds to the Aβ-derived diffusible ligands (ADDLs), which are believed to increase memory problems and brain cell death.…
JNJ-63733657 Focusing on early Alzheimer’s, this study tests the anti-tau antibody, JNJ-63733657, against a placebo, assessing its potential to slow disease progression. This study is for people who do not have an Alzheimer’s disease diagnosis or symptoms, rather they are…
Dysport In this clinical study, we are looking at the impact Dysport has on chronic and episodic migraines. The goal is to see if this Botulinum toxin injection reduces the number of days with migraines. Eligibility: For both the chronic…
Masupirdine This clinical trial is testing Masupirdine’s effectiveness on calming agitation that often affects those with Alzheimer’s disease. This oral medication is a selective antagonist of the 5-HT6 serotonin receptor. Eligibility: Individuals with Alzheimer’s disease with untreated agitation. Status: RECRUITING
Lu AG09222 This research explores the potential Lu AG09222 has to reduce migraine days more effectively than a placebo. Lu AG09222 is a anti-PACAP antibody that will inhibit PACAP. Eligibility: Individuals who have not found relief with 2-4 other treatments,…
HOPE This study assesses the impact the COGNITO device has on slowing Alzheimer’s disease’s progression. We measure the effects the device’s visual and audio stimulation has on the participant’s daily activities and cognitive functions. Eligibility: Individuals with mild to moderate…
PASEDENA This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients. Status: ACTIVE, NOT RECRUITING
Clarity AD Lecanemab antibody targets amyloid-beta plaques in the brain to potentially slow the progression of Alzheimer’s disease. This study examines its impact on cognitive function over 18 months, with an extension phase to monitor long-term safety and effects. Status:…
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi sagittis bibendum turpis, convallis faucibus purus sollicitudin at. Etiam ornare cursus turpis, eget finibus erat imperdiet quis. Etiam rutrum facilisis purus id porta. Praesent nibh nisl, elementum ac nibh non, ultrices blandit lectus. Nulla vitae tellus nec urna rhoncus iaculis blandit posuere dui. Suspendisse mattis, lectus…